Ventyx Biosciences Stock EBITDA
| VTYX Stock | USD 1.85 0.12 6.94% |
Ventyx Biosciences fundamentals help investors to digest information that contributes to Ventyx Biosciences' financial success or failures. It also enables traders to predict the movement of Ventyx Stock. The fundamental analysis module provides a way to measure Ventyx Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ventyx Biosciences stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -207.8 M | -197.4 M |
Ventyx | EBITDA |
Ventyx Biosciences Company EBITDA Analysis
Ventyx Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Ventyx Biosciences EBITDA | (207.84 M) |
Most of Ventyx Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ventyx Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ventyx EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Ventyx Biosciences is extremely important. It helps to project a fair market value of Ventyx Stock properly, considering its historical fundamentals such as EBITDA. Since Ventyx Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ventyx Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ventyx Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Ventyx Ebitda
According to the company disclosure, Ventyx Biosciences reported earnings before interest,tax, depreciation and amortization of (207.84 Million). This is 123.69% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 105.33% higher than that of the company.
Ventyx EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ventyx Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ventyx Biosciences could also be used in its relative valuation, which is a method of valuing Ventyx Biosciences by comparing valuation metrics of similar companies.Ventyx Biosciences is currently under evaluation in ebitda category among its peers.
Ventyx Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Ventyx Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ventyx Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ventyx Biosciences' value.| Shares | Vestal Point Capital Lp | 2024-06-30 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | State Street Corp | 2024-06-30 | 1.2 M | Parkman Healthcare Partners Llc | 2024-06-30 | 1.2 M | Sphera Funds Management Ltd. | 2024-09-30 | 1 M | Jpmorgan Chase & Co | 2024-06-30 | 987.3 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 568.5 K | Walleye Trading Advisors, Llc | 2024-06-30 | 510.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 485.1 K | Deerfield Management Co | 2024-09-30 | 6.7 M | Blackrock Inc | 2024-06-30 | 4.8 M |
Ventyx Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (132.97 M) | ||||
| Shares Outstanding | 70.71 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 84.87 % | ||||
| Number Of Shares Shorted | 8.14 M | ||||
| Price To Book | 0.47 X | ||||
| EBITDA | (207.84 M) | ||||
| Net Income | (192.96 M) | ||||
| Cash And Equivalents | 250.45 M | ||||
| Cash Per Share | 4.92 X | ||||
| Total Debt | 12.51 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.27 X | ||||
| Book Value Per Share | 3.94 X | ||||
| Cash Flow From Operations | (166.52 M) | ||||
| Short Ratio | 9.91 X | ||||
| Earnings Per Share | (2.35) X | ||||
| Target Price | 10.5 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 130.81 M | ||||
| Total Asset | 277.69 M | ||||
| Retained Earnings | (419.19 M) | ||||
| Working Capital | 242.08 M | ||||
| Net Asset | 277.69 M |
About Ventyx Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ventyx Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ventyx Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ventyx Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.